![]() |
Trials |
DurSab - Stereotactic Ablative Body Radiotherapy (SABR) followed by Durvalumab as maintenance treatment in patients with advanced non-small cell lung cancer not progressing after 4 to 6 cycles of first-line conventional chemotherapyCancer type: Lung cancer Phase: I Principal Investigator: de Petris Luigi Country: SE Keywords: Durvalumab, stereotactic radiotherapy, non-small cell lung cancer, Sweden, Stockholm, Karolinska Status: Open for inclusion |